文献速递临床试验与 GCP基础与转化研究

静脉干扰素β-1a对中重度ARDS患者死亡及无机械通气天数的影响:随机临床试验

Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项多中心随机双盲试验在8个欧洲国家74个ICU纳入301例中重度ARDS成人患者,比较静脉注射IFN-β-1a 10μg每日一次共6天与安慰剂的疗效。结论不支持IFN-β-1a用于ARDS管理。

要点

  • 中重度ARDS患者使用IFN-β-1a 6天未改善28天死亡与无机械通气天数复合评分。
  • 28天死亡率IFN-β-1a组26.4% vs 安慰剂组23.0%,差异无统计学意义。
  • 治疗相关不良事件IFN-β-1a组28.5% vs 安慰剂组21.7%。

核心结论

  • 在中重度ARDS成人患者中,静脉IFN-β-1a治疗6天与安慰剂相比,28天内死亡和无机械通气天数的复合评分无显著差异。
  • 结果不支持IFN-β-1a用于ARDS的临床管理。

研究设计与样本

  • 纳入301例符合柏林定义的中重度ARDS成人患者,随机接受静脉IFN-β-1a 10μg(144例)或安慰剂(152例),每日一次共6天。
  • 主要终点为第28天死亡与无机械通气天数的复合评分(死亡计-1分,若第1天脱离呼吸机计27分)。

主要发现

  • 研究期间74例(25.0%)发生被认为与治疗相关的不良事件,IFN-β-1a组41例(28.5%),安慰剂组33例(21.7%)。

临床怎么用

  • 现有证据不支持在中重度ARDS成人患者中使用静脉IFN-β-1a改善无机械通气天数或降低死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acute respiratory distress syndrome (ARDS) is associated with high mortality. Interferon (IFN) β-1a may prevent the underlying event of vascular leakage. OBJECTIVE: To determine the efficacy and adverse events of IFN-β-1a in patients with moderate to severe ARDS. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, parallel-group trial conducted at 74 intensive care units in 8 European countries (December 2015-December 2017) that included 301 adults with moderate to severe ARDS according to the Berlin definition. The radiological and partial pressure of oxygen, arterial (Pao2)/fraction of inspired oxygen (Fio2) criteria for ARDS had to be met within a 24-hour period, and the administration of the first dose of the study drug had to occur within 48 hours of the diagnosis of ARDS. The last patient visit was on March 6, 2018. INTERVENTIONS: Patients were randomized to receive an intravenous injection of 10 μg of IFN-β-1a (144 patients) or placebo (152 patients) once daily for 6 days. MAIN OUTCOMES AND MEASURES: The primary outcome was a score combining death and number of ventilator-free days at day 28 (score ranged from -1 for death to 27 if the patient was off ventilator on the first day). There were 16 secondary outcomes, including 28-day mortality, which were tested hierarchically to control type I error. RESULTS: Among 301 patients who were randomized (mean age, 58 years; 103 women [34.2%]), 296 (98.3%) completed the trial and were included in the primary analysis. At 28 days, the median composite score of death and number of ventilator-free days at day 28 was 10 days (interquartile range, -1 to 20) in the IFN-β-1a group and 8.5 days (interquartile range, 0 to 20) in the placebo group (P = .82). There was no significant difference in 28-day mortality between the IFN-β-1a vs placebo groups (26.4% vs 23.0%; difference, 3.4% [95% CI, -8.1% to 14.8%]; P = .53). Seventy-four patients (25.0%) experienced adverse events considered to be related to treatment during the study (41 patients [28.5%] in the IFN-β-1a group and 33 [21.7%] in the placebo group). CONCLUSIONS AND RELEVANCE: Among adults with moderate or severe ARDS, intravenous IFN-β-1a administered for 6 days, compared with placebo, resulted in no significant difference in a composite score that included death and number of ventilator-free days over 28 days. These results do not support the use of IFN-β-1a in the management of ARDS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02622724.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2020. PMID: 32065831. doi:10.1001/jama.2019.22525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。